The effect of compound Kushen Injection combined with chemotherapy and bevacizumab on short-term efficacy of patients with ovarian cancer

doi:10.11958/20252396

Abstract

Abstract:

Objective To investigate the influence of compound Kushen injection combined with chemotherapy and bevacizumab on short-term efficacy and inflammatory factor levels in patients with ovarian cancer. Methods A retrospective study was conducted on 92 patients with ovarian cancer. Patients were divided into the control group (47 cases) and the observation group (45 cases) according to different treatment regimens. The control group was treated with paclitaxel + platinum + bevacizumab, while the observation group received the same regimen plus compound Kushen injection. The short-term efficacy, human epididymis protein 4 (HE4), carbohydrate antigen 125 (CA125), vascular endothelial growth factor (VEGF), transforming growth factor-β1 (TGF-β1) and incidence of adverse reactions were compared before and after treatment between the two groups. Results The objective response rate was 80.0% in the observation group, which was higher than 59.6% in the control group (P<0.05). After treatment, HE4, CA125, VEGF and TGF-β1 levels were significantly lower in the observation group than those in the control group (P<0.05). There were no significant differences in incidence of gastrointestinal reactions, myelosuppression and liver/kidney function abnormalities between the two groups of patients (P>0.05). Conclusion Compound Kushen injection combined with chemotherapy and bevacizumab has significant therapeutic efficacy and high safety in the treatment of patients with ovarian cancer.

Key words: ovarian neoplasms, Fu Fang Ku Shen Zhu She Ye, chemotherapy, vascular endothelial growth factor A, transforming growth factor beta 1, bevacizumab

CLC Number:

R737.31，R273

Figures/Tables 5

References 24

[1]	SUNG H, FERLAY J, SIEGEL R L, et al. Global Cancer Statistics 2020:GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2021, 71(3):209-249. doi:10.3322/caac.21660.
[2]	ZAPARDIEL I, DIESTRO M D, ALETTI G. Conservative treatment of early stage ovarian cancer:oncological and fertility outcomes[J]. Eur J Surg Oncol, 2014, 40(4):387-393. doi:10.1016/j.ejso.2013.11.028.
[3]	凌小婷, 徐国才, 林荣春, 等. 晚期卵巢癌腹腔化疗联合静脉化疗用于新辅助化疗Ⅰ期临床试验研究[J]. 中国实用妇科与产科杂志, 2019, 35(12):1345-1349.
	LING X Y, XU G C, LIN R C, et al. Intraperitoneal chemotherapy combined with intravenous chemotherapy for neoadjuvant chemotherapy in advanced ovarian cancer:a phase Ⅰ clinical trial[J]. Chinese Journal of Practical Gynecology and Obstetrics, 2019, 35(12):1345-1349. doi:10.19538/j.fk2019120114.
[4]	卢雯平, 白萍, 田小飞, 等. 卵巢癌中西医结合诊疗指南[J]. 中国医药, 2024, 19(5):641-648.
	LU W P, BAI P, TIAN X F, et al. Guideline for diagnosis and treatment of ovarian cancer with integrated traditional Chinese and western medicine[J]. China Medicine, 2024, 19(5):641-648. doi:10.3760/j.issn.1673-4777.2024.05.001.
[5]	李丽华, 宋俊莉, 杨幸繁. 贝伐珠单抗联合紫杉醇、卡铂治疗复发性卵巢癌的疗效及对血清糖类抗原125、人附睾蛋白4水平的影响[J]. 癌症进展, 2020, 18(16):1708-1711,1727.
	LI L H, SONG J L, YANG X F, et al. Efficacy of bevacizumab combined with paclitaxel and carboplatin in the treatment of recurrent ovarian cancer and its effect on serum carbohydrate antigen 125 and human epididymal protein 4 levels[J]. Oncology Progress, 2020, 18(16):1708-1711,1727. doi:10.11877/j.issn.1672-1535.2020.18.16.24.
[6]	中国临床肿瘤学会指南工作委员会. 卵巢癌诊疗指南2023[M]. 北京: 人民卫生出版社,2023:10-13.
	Guidelines Working Committee of the Chinese Society of Clinical Oncology. Guidelines for diagnosis and treatment of ovarian cancer 2023[M]. Beijing: People's Health Publishing House,2023:10-13.
[7]	EISENHAUER E A, THERASSE P, BOGAERTS J, et al. New response evaluation criteria in solid tumours:revised RECIST guideline (version 1.1)[J]. Eur J Cancer, 2009, 45(2):228-247. doi:10.1016/j.ejca.2008.10.026.
[8]	DAI L, LIU Y, XIE L, et al. Sphingosine kinase 1/sphingosine-1-phosphate(S1P)/S1P receptor axis is involved in ovarian cancer angiogenesis[J]. Oncotarget, 2017, 8(43):74947-74961. doi:10.18632/oncotarget.20471.
[9]	喻萍, 周敏, 苏丹. 卵巢癌化疗耐药预测模型的建立及效果评价[J]. 天津医药, 2024, 52(11):1177-1183.
	YU P, ZHOU M, SU D. Construction and validation of chemotherapy resistance prediction model for ovarian cancer[J]. Tianjin Med J, 2024, 52(11):1177-1183. doi:10.11958/20240546.
[10]	DUAN X, YANG B, ZHAO C, et al. Prognostic value of preoperative hematological markers in patients with glioblastoma multiforme and construction of random survival forest model[J]. BMC Cancer, 2023, 23(1):432. doi:10.1186/s12885-023-10889-0.
[11]	PETITJEAN A, SMITH-PALMER J, VALENTINE W, et al. Cost-effectiveness of bevacizumab plus paclitaxel versus paclitaxel for the first-line treatment of HER2-negative metastatic breast cancer in specialist oncology centers in France[J]. BMC Cancer, 2019, 19(1):140. doi:10.1186/s12885-019-5335-8.
[12]	崔晓娟, 陆晓兰, 冯炜炜. 载紫杉醇的聚乙二醇聚丙交酯-乙交酯聚赖氨酸纳米粒制备及其对耐药卵巢癌细胞的作用[J]. 中国新药与临床杂志, 2020, 39(9):552-557.
	CUI X J, LU X L, FENG W W. Preparation of paclitaxel-loaded mPEG-PLGA-PLL nanoparticles and their effects on drug-resistant ovarian cancer cells[J]. Chinese Journal of New Drugs and Clinical Remedies, 2020, 39(9):552-557. doi:10.14109/j.cnki.xyylc.2020.09.10.
[13]	王真, 翟永宁. 紫杉醇联合卡铂对卵巢癌患者的有效性及患者血清TNF-α、CA125水平的影响[J]. 中国性科学, 2019, 28(10):33-36.
	WANG Z, ZHAI Y N. Effect of paclitaxel combined with carboplatin on ovarian cancer patients and their serum TNF-α and CA125 levels[J]. Chinese Journal of Human Sexuality, 2019, 28(10):33-36. doi:10.3969/j.issn.1672-1993.2019.10.009.
[14]	张新, 高雁荣, 黄伟娟, 等. 奥拉帕利联合贝伐珠单抗方案对卵巢癌患者近期疗效及血清P-selectin、sICAM-1水平的影响[J]. 中国医学工程, 2024, 32(4):59-63.
	ZHANG X, GAO Y R, HUANG W J, et al. Effects of olaparib combined with bevacizumab regimen on short term efficacy and serum P-selectin,sICAM-1 levels in patients with ovarian cancer[J]. China Medical Engineering, 2024, 32(4):59-63. doi:10.19338/j.issn.1672-2019.2024.04.013.
[15]	曹金芳. 复方苦参注射液联合放化疗治疗宫颈癌的临床观察[J]. 中国民间疗法, 2019, 27(22):64-65.
	CAO J F. Clinical observation of compound Sophora flavescens injection combined with radiotherapy and chemotherapy in the treatment of cervical cancer[J]. China's Naturopathy, 2019, 27(22):64-65. doi:10.19621/j.cnki.11-3555/r.2019.2233.
[16]	刘婷, 王文萍. 复方苦参注射液联合TP方案化疗在肺癌、卵巢癌、宫颈癌治疗中网状Meta分析[J]. 辽宁中医药大学学报, 2023, 25(4):144-152.
	LIU T, WANG W P. Network Meta-analysis of compound Fufang Kushen injection combined with TP chemotherapy in lung cancer,ovarian cancer and cervical cancer[J]. Journal of Liaoning University of Traditional Chinese Medicine, 2023, 25(4):144-152. doi:10.13194/j.issn.1673-842x.2023.04.032.
[17]	肖义森, 杨丽梅, 潘国基, 等. 探讨血清肿瘤标志物糖类抗原125、糖类抗原19-9、甲胎蛋白和癌胚抗原在卵巢肿瘤诊断中的临床价值[J]. 中国现代药物应用, 2019, 13(10):50-51.
	XIAO Y S, YANG L M, PAN G J, et al. Exploring the clinical value of serum tumor markers carbohydrate antigen 125,carbohydrate antigen 19-9,alpha fetoprotein,and carcinoembryonic antigen in the diagnosis of ovarian tumors[J]. Chinese Journal of Modern Drug Application, 2019, 13(10):50-51. doi:10.14164/j.cnki.cn11-5581/r.2019.10.026.
[18]	贾素娟, 王治洁, 张美琴, 等. 血清CA125、HE4和影像学检查在上皮性卵巢癌术后复发诊断中的应用价值[J]. 中国癌症杂志, 2015, 25(6):452-456.
	JIA S J, WANG Z J, ZHANG M Q, et al. The value of serum CA125,HE4 and imaging examinations in detecting the recurrence of postoperative ovarian cancer[J]. China Oncology, 2015, 25(6):452-456. doi:10.3969/j.issn.1007-3969.2015.06.008.
[19]	杨红耀, 郭哲, 张欣贺. Piezo1、VEGF在上皮性卵巢癌组织中的表达及与其临床病理特征相关性分析[J]. 实用癌症杂志, 2023, 38(4):558-561.
	YANG H Y, GUO Z, ZHANG X H. Expression of Piezo1 and VEGF in epithelial ovarian cancer and their correlation with clinicopathological characteristics[J]. The Practical Journal of Cancer, 2023, 38(4):558-561. doi:10.3969/j.issn.1001-5930.2023.04.009.
[20]	PARVATHAREDDY S K, SIRAJ A K, AL-BADAWI I A, et al. Differential expression of PD-L1 between primary and metastatic epithelial ovarian cancer and its clinico-pathological correlation[J]. Sci Rep, 2021, 11(1):3750. doi:10.1038/s41598-021-83276-z.
[21]	全碧波. 参葵汤对卵巢癌模型大鼠淋巴细胞、免疫球蛋白及相关炎症因子的影响分析[J]. 中医临床研究, 2019, 11(24):97-98.
	QUAN B B. Effects of Shenkui Decoction on lymphocyte,immunoglobulin and related inflammatory factor in ovarian cancer model rats[J]. Clinical Journal of Chinese Medicine, 2019, 11(24):97-98. doi:10.3969/i.issn.1674-7860.2019.24.042.
[22]	刘海燕, 官燕, 孙颖, 等. 腹腔内贝伐珠单抗联合热化疗对老年卵巢癌患者血转化生长因子β1和巨噬细胞移动抑制因子水平的影响[J]. 中华老年医学杂志, 2018, 37(4):434-436.
	LIU H Y, GUAN Y, SUN Y, et al. The effect of abdominal Bevacizumab combined with hyperthermia chemotherapy on serum transforming growth factor beta 1 and migration-inhibitory factor levels in elderly patients with ovarian cancer[J]. Chinese Journal of Geriatrics, 2018, 37(4):434-436. doi:10.3760/cma.j.issn.0254-9026.2018.04.019.
[23]	贾英杰, 张莹, 史福敏. 复方苦参注射液对小鼠移植性S180肉瘤血管形成抑制作用[J]. 天津中医学院学报, 2006, 25(1):25-26.
	JIA Y J, ZHANG Y, SHI F M. Sarcoma by Fufangkushen Injection experimental study on inhibiting angiogenesis in mice S180[J]. Journal of Tianjin College of Traditional Chinese Medicine,2006, 25(1): 25-26. doi:1005-7145(2006)01-0025-02.
[24]	赵艳勋, 刘苓, 卢玲, 等. 复方苦参注射液对卵巢癌化疗患者生活质量及治疗疗效影响研究[J]. 中国临床医生杂志, 2018, 46(1):89-91.
	ZHAO Y X, LIU L, LU L, et al. Study on the effect of Compound Kushen Injection on the quality of life and therapeutic efficacy of ovarian cancer chemotherapy patients[J]. Chinese Journal of Clinical Physicians, 2018, 46(1):89-91. doi:10.3969/j.issn.2095-8552.2018.01.032.

组别		n	年龄/岁		BMI/（kg/m²）
对照组		47	50.55±8.62		21.37±2.56
观察组		45	54.38±12.21		21.03±2.39
t			1.741		0.660
组别	FIGO分期			病理类型
组别	Ⅱ期	Ⅲ期	Ⅳ期	高级别浆液性癌	透明细胞癌	子宫内膜样癌
对照组	4（8.5）	41（87.2）	2（4.3）	44（93.6）	1（2.1）	2（4.3）
观察组	3（6.7）	40（88.9）	2（4.4）	44（97.8）	1（2.2）	0（0.0）
χ²	0.291			1.828

组别		n	年龄/岁		BMI/（kg/m²）
对照组		47	50.55±8.62		21.37±2.56
观察组		45	54.38±12.21		21.03±2.39
t			1.741		0.660
组别	FIGO分期			病理类型
组别	Ⅱ期	Ⅲ期	Ⅳ期	高级别浆液性癌	透明细胞癌	子宫内膜样癌
对照组	4（8.5）	41（87.2）	2（4.3）	44（93.6）	1（2.1）	2（4.3）
观察组	3（6.7）	40（88.9）	2（4.4）	44（97.8）	1（2.2）	0（0.0）
χ²	0.291			1.828

组别	n	完全缓解	部分缓解	疾病稳定	疾病进展	客观缓解
对照组	47	10（21.3）	18（38.3）	13（27.7）	6（12.7）	28（59.6）
观察组	45	15（33.3）	21（46.7）	6（13.3）	3（6.7）	36（80.0）
χ²						4.530^＊

组别	n	完全缓解	部分缓解	疾病稳定	疾病进展	客观缓解
对照组	47	10（21.3）	18（38.3）	13（27.7）	6（12.7）	28（59.6）
观察组	45	15（33.3）	21（46.7）	6（13.3）	3（6.7）	36（80.0）
χ²						4.530^＊

组别	n		HE4/（pmol/L）
组别	n		治疗前		治疗后		t
对照组	47		566.36±163.72		121.38±56.33		17.648^＊＊
观察组	45		530.56±104.77		79.89±24.69		27.521^＊＊
t			1.243		4.541^＊＊
组别		CA125/（U/mL）
组别		治疗前		治疗后		t
对照组		1 464.23±239.84		394.49±94.38		11.373^＊＊
观察组		1 355.71±395.82		96.07±87.64		20.103^＊＊
t		1.598		15.699^＊＊